Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma

Genes Dis. 2022 Dec 24;10(5):1755-1758. doi: 10.1016/j.gendis.2022.11.014. eCollection 2023 Sep.

Ruixin Jiang^{1

2}, Xianbin Liang³, Ye Tao^{1

2}, Ronghui Xia⁴, Ming Lei², Bin Jiang¹, Robert L Judson-Torres^{5

6}, Yanjie Zhang^{1

2}, Weizhen Zhang³, Hanlin Zeng^{1

2}

¹ Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China.
² Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China.
³ Department of Oncology, The Third People's Hospital of Zhengzhou; Zhengzhou, Henan 450000, China.
⁴ Department of Oral & Maxillofacial - Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China.
⁵ Department of Dermatology, University of Utah, Salt Lake City, UT 84132, USA.
⁶ Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.

No abstract available